Allergy Therapeutics Share Discussion Threads

[coinbase] 29/10/2024 12:57

LSE SETSqx - hXXps://www.londonstockexchange.com/equities-trading/asset-classes/shares-trading/setsqx-and-seaq

[coinbase] 29/10/2024 12:54

Level 2 - hXXp://uk.advfn.com/offers/level2

[vergeltung] 29/10/2024 09:57

@coinbase, where is this information available? I have the Stock Exchange info, but I often think it's questionable - trades of tiny numbers (59 shares, 34 shares)which clearly makes no sense if the cost of trading is anything >0 ...

[coinbase] 29/10/2024 08:51

This morning’s auction is alive and kicking with 3 blocks of 100,000 shares on the ask from 5.22 to 5.3 GBX.

[totally banjo] 28/10/2024 10:21

Yep, the potential for AGY is huge!

Results this week or next will be interesting regarding sale figures from existing products along with any updates on the ongoing trials and approvals will be a bonus!

[jimmyloser] 28/10/2024 10:03

Not just in Europe and USA but...........transforming the lives of millions of patients around the world."

Around the world.......they would need a global player for that.

Hold a tiger by the tail?

impo

[jimmyloser] 27/10/2024 11:28

What an exciting time to be a shareholder in AGY. Impo/Dyor etc
With Prelim results imminent and likely to tell us about increased productivity and efficiency resulting in growth in sales as indicated in the recent funding RNS.

We also have the much awaited marketing application for Grass Mata (see below) and the update in Q4 of the biomarker data (much awaited and see below)

It has been a turbulent ride across several years, but hey ho, it has been interesting and educational.

PROTECT – Peanut
The preliminary results from the first two cohorts of peanut allergic patients assessing safety and efficacy are expected in Q4 2024.


Allergy Therapeutics announces successful meetings with Paul Ehrlich Institut to enable MAA plans for Grass MATA MPL
Collaborative meetings held with the Paul Ehrlich Institut (PEI) to discuss proposed Chemistry, Manufacture and Controls (CMC) and clinical packages in support of upcoming Grass MATA MPL Marketing Authorisation Application (MAA), on track for submission in Q4 2024
- By including patients from the US, the G306 and G309 trials were designed as supportive to enable a pathway for Biologics License Application (BLA) in the US

3 June 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces updates on progression of the Group's MAA preparation for Grass MATA MPL.

Developing a comprehensive data package
Positive regulatory discussions have been held with the PEI regarding the results of the pivotal G306 Phase III trial, as well as the data in support of CMC requirements and the subsequent regulatory pathway to national registration of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

During the meetings, key trial data from the pivotal G306 Phase III trial were shared, alongside supporting CMC data that the Group plans to use as the basis for the proposed marketing authorisation application. Feedback was constructive and PEI confirmed that, subject to the usual regulatory approval procedures and detailed data analysis, the Group may proceed with an MAA. As previously announced, the Group intends to submit an MAA in Q4 2024.

Supportive of US strategy
Completion of the G309 and G306 field studies represents a significant milestone in plans for registration in the US. Following an earlier successful end of phase 2 meeting with FDA, the subsequent studies were designed to support a pathway forward to BLA in the US with both G309 and G306 studies including US subjects and it is also planned to include US subjects in the upcoming paediatric study G308. As previously communicated, a specific requirement for FDA, will involve a further study known as G307 to meet the required total number of US subjects treated using the product intended for registration and the Group are planning for meetings with the FDA to agree a route forward. Immediate focus will be preparing the data package for national MAA in Q4 alongside exploration for potential collaborations for US expansion.

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We appreciate the supportive and helpful discussions with the PEI and are very pleased that preparations for the regulatory submission of our Grass MATA MPL immunotherapy candidate remain on track. Bringing Grass MATA MPL to this stage has been a huge undertaking for a company like us. After many years and significant investment, we are extremely encouraged by the possibility of bringing this state-of-the-art vaccine to the market, transforming the lives of millions of patients around the world."

[jimmyloser] 25/10/2024 19:43

Next week should set the scene.

[jpuff] 25/10/2024 19:39

Looks nice technically

[totally banjo] 25/10/2024 18:34

Well, it's ticking up slowly but surely!

[coinbase] 24/10/2024 20:07

Joeblogg2, are you (forward) spread betting?

[coinbase] 23/10/2024 13:32

This afternoon's paired trades are (forward) spread bets.

[totally banjo] 21/10/2024 16:37

Is that tick up the sign of mm's been filling an order.,... probably not :-)

Anyway I'll be in for a few more in a few weeks when I get my 25% tax free lumper from pension so share price can go down please

[totally banjo] 21/10/2024 13:29

I think this report is a few years old but was highlighted today, I wouldn't bother purchasing as it's about $4000!

What it again shows is the rising trend in allergies on a global scale and hence the rise in the market for allergy treatments!

House Dust Mite Allergy Treatment Market Set to Hit $5.2B by 2031, with Asia-Pacific Leading Growth at 14.4% CAGR

News Provided By
Allied Analytics LLP
October 21, 2024, 11:09 GMT

PORTLAND, OR, UNITED STATES, October 21, 2024 /EINPresswire.com/ -- The global house dust mite allergy treatment market is experiencing substantial growth, driven by increasing awareness of allergic diseases and advancements in pharmaceutical research. This article explores key factors contributing to the market's expansion, its segmentation, and emerging trends.

The global house dust mite allergy treatment market is poised for significant growth, driven by rising awareness, increased healthcare spending, and advancements in drug development. With a robust pipeline of treatments and growing market participation, stakeholders have ample opportunities to capitalize on this expanding sector. As hygiene practices improve and the understanding of allergies deepens, the market will continue to evolve, promising innovative solutions for allergy sufferers worldwide.


Market Overview
• Market Size:
• Valued at $1.5 billion in 2021.
• Projected to reach $5.2 billion by 2031.
• Growth Rate:
• Expected CAGR of 13.4% from 2022 to 2031.


Key Players
Prominent companies in the global house dust mite allergy treatment market include:
• ALK-Abello A/S
• Allergy Therapeutics PLC
• Bayer AG
• Catalent Pharma Solutions Limited
• GlaxoSmithKline Plc.
• Johnson and Johnson
• Merz Pharma GmbH and Co. KGaA
• Sanofi
• Seqirus UK Limited
• Shionogi & Co. Ltd.

hxxps://www.einpresswire.com/article/753510800/house-dust-mite-allergy-treatment-market-set-to-hit-5-2b-by-2031-with-asia-pacific-leading-growth-at-14-4-cagr


hxxps://www.alliedmarketresearch.com/house-dust-mite-allergy-treatment-market-A16570#toc

[jimmyloser] 21/10/2024 12:20

Let me add to 5096 above. It is news of monetising our new wonder drugs that will get the market excited and less so another set of trials as important as they are.
The thought of it materialising has clearly got our backers frothy already.

No ramp intended, but todays price is chicken feed compared to where this may well be headed.

impo/dyor et al etc

[totally banjo] 21/10/2024 10:48

Just to clarify the G308 Grass MATA MPL trial (announced today) is obviously for children while the G306 trial was for adults.

The G306 Grass MATA MPL trial for adults has been completed and starts the German approval stage (plan was Q4 2024) with results due roughly in mid/late 2025 and if granted will see this product being sold within the largest allergen immunotherapy market in Europe! This would then forward to a USA approval route which if successful gives access (est. 2027) to a $2bn market!

[jimmyloser] 21/10/2024 10:43

My take is this is really significant news in the grand scheme of things and the market just wants the prelims to give them confidence.

In my time in AGY, I have never seen them looking as capable of finally delivering!

impo

[totally banjo] 21/10/2024 10:33

It appears the market doesn't like or indeed appreciate the various ongoing trials, the market will catch up in time!

[wizzkid211] 21/10/2024 06:03

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")



Allergy Therapeutics commences Phase III paediatric trial for Grass MATA MPL



· Industry first long-term subcutaneous allergen-specific immunotherapy (SCIT) trial for grass pollen in paediatric subjects

· Patient screening and enrolment underway with topline safety and efficacy data expected Q4 2025



21 October 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first subjects have been screened and enrolled in the Group's Phase III G308 trial to evaluate the long-term efficacy and safety of Grass MATA MPL in paediatric subjects.



Grass MATA MPL is the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

Incorporating MicroCrystalline Tyrosine ("MCT®") adsorbed allergoids and the innovative adjuvant Monophosphoryl-lipid A ("MPL"), the immunotherapy candidate has been developed to modify the allergic response following only six injections prior to the grass allergy season.



Commencement of the G308 paediatric trial follows the successful earlier completion of the Group's pivotal Phase III G306 trial in adults. In that trial, Grass MATA MPL demonstrated a highly statistically significant reduction in the Combined Symptom & Medication Score (CSMS) compared to placebo over the peak pollen season. Building on these positive results, G308 is designed to evaluate the long-term efficacy and safety of the immunotherapy candidate in a paediatric population over five years. Topline safety and efficacy data are expected in Q4 2025.



The G308 paediatric trial complements Allergy Therapeutics' previous studies in adults, including the pivotal Phase III G306 trial and the exploratory G309 field study, furthering the Group's comprehensive development strategy for Grass MATA MPL across different age groups.



Manuel Llobet, CEO of Allergy Therapeutics, commented: "The commencement of our long-term paediatric Phase III trial (G308) marks the first time a SCIT grass pollen vaccine has been evaluated in a paediatric population over the long-term, a significant milestone in the allergy industry. Encouraged by the results of our short-course grass pollen immunotherapy in both the successful G309 exploratory field trial and the pivotal G306 trial, we are excited to advance the development of this innovative treatment candidate in new patient populations, potentially offering a transformative option for children with grass pollen allergies."

[totally banjo] 18/10/2024 17:57

A little tick up!

[farmergeorge] 18/10/2024 15:06

jimmyloser, nice that we are getting positive vibes. This now needs to be reflected in the share price.

[jimmyloser] 18/10/2024 13:16

FarmerG,
Good to have you back, even you are in a naughty mood! lol.

I expect results as soon as Monday with the most upbeat outlook yet from AGY. As Coin made comment last night "It is what is going on under the hood" that we will hear more of and then the interest will rise (impo)
Let me add, I agree with Banjo, this IS lining up to be the potential """blockbuster""" that the Daily Mail mentioned.

[totally banjo] 18/10/2024 12:57

No worries farmer g

[farmergeorge] 18/10/2024 12:48

totally banjo, I appreciate all of that which is great news for us holders. I was merely being sarcastic, which the previous form of the company invites.

[totally banjo] 18/10/2024 12:15

farmer g, there has been a lot going on in the background regarding their existing product range! As in increasing the manufacturing base to meet the demand which we hopefully will see progress in the upcoming preliminary results.

The ongoing trials and approvals are the main points of interest and they are completely out of AGY's control! The results of which are massively transformational for AGY as a company, like hugely massive :-). This obviously takes time!